Psyence BioMed welcomes U.S. action to speed ibogaine development
Psyence BioMed says it welcomes the U.S. administration’s latest action to accelerate ibogaine development.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.